Business Context and Reporting Period
This Form 8-K Current Report was filed by Corvus Pharmaceuticals, Inc. on September 10, 2020. The filing reports the election of a new director to the Board of Directors and details the associated compensatory arrangements.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and director compensation.
Material Changes
The primary material change reported is the appointment of Edith P. Mitchell, M.D. as a director and member of the Nominating and Corporate Governance Committee, effective September 10, 2020. Dr. Mitchell serves as a Class II director with a term expiring at the 2021 annual meeting of stockholders.
Guidance, Outlook, and Compensation Details
The filing outlines the specific compensation package for Dr. Mitchell under the Non-Employee Director Compensation Program:
- Cash Retainer: $35,000 annual retainer for Board service plus an additional $4,000 annual retainer for Committee service.
- Initial Equity Award: An option to purchase 30,000 shares of Common Stock granted on the appointment date. This award vests in three equal installments (1/3) on each yearly anniversary of the appointment date, subject to continued service.
- Subsequent Equity Awards: Eligibility for annual grants of 15,000 shares, vesting on the earlier of the first anniversary of the grant date or the next annual stockholders' meeting.
- Change in Control: All equity awards vest in full immediately prior to a change in control.
- Indemnification: The Company will enter into a standard indemnification agreement with Dr. Mitchell.
The filing confirms there are no transactions exceeding $120,000 involving Dr. Mitchell since the beginning of the last fiscal year and no other arrangements regarding her appointment.
Investor Verification Checklist
- Verify the impact of the new director's expertise in oncology and cancer disparities on the Company's strategic direction.
- Review the total number of shares reserved under the 2016 Equity Incentive Award Plan to assess dilution from the 30,000 share initial grant.
- Confirm the current fair market value of the Common Stock to determine the exercise price of the granted options.
- Check subsequent filings for the execution of the Indemnification Agreement referenced in Exhibit 10.6.